Relapsing Remitting Multiple Sclerosis- Pipeline Insight, 2022

DelveInsight’s, “Relapsing Remitting Multiple Sclerosis- Pipeline Insight, 2022,” report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in Relapsing Remitting Multiple Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage
Relapsing Remitting Multiple Sclerosis Understanding
Relapsing Remitting Multiple Sclerosis: Overview
RRMS – the most common disease course – is characterized by clearly defined attacks of new or increasing neurologic symptoms. These attacks – also called relapses or exacerbations – are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during the periods of remission. RRMS can be further characterized as either active (with relapses and/or evidence of new MRI activity over a specified period of time) or not active, as well as worsening (a confirmed increase in disability following a relapse) or not worsening. Approximately 85 percent of people with MS are initially diagnosed with RRMS. Relapsing-remitting MS is defined by inflammatory attacks on myelin (the layers of insulating membranes surrounding nerve fibers in the central nervous system (CNS)), as well as the nerve fibers themselves. During these inflammatory attacks, activated immune cells cause small, localized areas of damage which produce the symptoms of MS. Because the location of the damage is so variable, no two people have exactly the same symptoms.

""Relapsing Remitting Multiple Sclerosis- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsing Remitting Multiple Sclerosis pipeline landscape is provided which includes the disease overview and Relapsing Remitting Multiple Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Relapsing Remitting Multiple Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing Remitting Multiple Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Relapsing Remitting Multiple Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Relapsing Remitting Multiple Sclerosis.

Relapsing Remitting Multiple Sclerosis Emerging Drugs Chapters
This segment of the Relapsing Remitting Multiple Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsing Remitting Multiple Sclerosis Emerging Drugs
Ublituximab: TG Therapeutics
Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell. Additionally, ublituximab is uniquely designed, to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, has been shown to enhance the potency of ublituximab, especially the ADCC activity. In September 2021, TG Therapeutics announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis (RMS). The submission was based on the results of the ULTIMATE I & II trials, two identical Phase 3, randomized, global, multi-center, double-blinded, active-controlled trials evaluating ublituximab compared to teriflunomide in patients with RMS. The ULTIMATE I & II trials were conducted under a Special Protocol Assessment (SPA) agreement with the FDA.
Vidofludimus calcium – Immunic
Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is currently being investigated in Phase 3 stage of development for the treatment of RRMS.
Evobrutinib - Merck Serono
Evobrutinib, is an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) which is thought to be important in the development and functioning of various immune cells including B lymphocytes and macrophages. The drug is currently being investigated in Phase 3 stage of development for the treatment of RRMS.
ANK-700: ANOKION
ANK-700 is an investigational treatment for RRMS. It encompasses a previously identified myelin antigen that is implicated in driving Multiple Sclerosis. The antigen is delivered to the liver and immune system with the liver targeting glycosylation signature. The drug is currently in Phase I stage of clinical trila evaluation to treat multiple sclerosis.
Orelabrutinib - InnoCare Pharma
Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of multiple sclerosis, orelabrutinib is a BTKi with high selectivity and ability to cross the blood-brain barrier and could achieve high-target occupancy in the central nervous system. It is currently being investigated in a global Phase 2 study in RRMS patients.
Further product details are provided in the report……..

Relapsing Remitting Multiple Sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Relapsing Remitting Multiple Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Relapsing Remitting Multiple Sclerosis
There are approx. 38+ key companies which are developing the therapies for Relapsing Remitting Multiple Sclerosis. The companies which have their Relapsing Remitting Multiple Sclerosis drug candidates in the most advanced stage, i.e. phase III include, Immunic
Phases
DelveInsight’s report covers around 38+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Relapsing Remitting Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type

Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsing Remitting Multiple Sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsing Remitting Multiple Sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsing Remitting Multiple Sclerosis drugs.

Relapsing Remitting Multiple Sclerosis Report Insights
Relapsing Remitting Multiple Sclerosis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Relapsing Remitting Multiple Sclerosis Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Relapsing Remitting Multiple Sclerosis drugs?
How many Relapsing Remitting Multiple Sclerosis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsing Remitting Multiple Sclerosis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsing Remitting Multiple Sclerosis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Relapsing Remitting Multiple Sclerosis and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
InnoCare Pharma
Biocad
Biogen
RedHill Biopharma Limited
Immunic AG
Merck Serono
Anokion SA
Apitope Technology
Neurotec Pharma
Mitsubishi Tanabe Pharma Corporation
TG Therapeutics, Inc.
RemeGen Co., Ltd.
Gilead Sciences
GlaxoSmithKline
GeNeuro SA
InteKrin Therapeutics, Inc.
Clene Nanomedicine
Takeda Pharmaceuticals
Mapi Pharma Ltd.

Key Products
BIIB-019
RHB-104
IMU-838
Evobrutinib
ANK-700
NT-KO-003
MT-1303
Belimumab
GNbAC1
INT131

Companies

InnoCare Pharma
Biocad
Biogen
RedHill Biopharma Limited
Immunic AG
Merck Serono
Anokion SA
Apitope Technology
Neurotec Pharma
Mitsubishi Tanabe Pharma Corporation
TG Therapeutics, Inc.
RemeGen Co., Ltd.
Gilead Sciences
GlaxoSmithKline
GeNeuro SA
InteKrin Therapeutics, Inc.
Clene Nanomedicine
Takeda Pharmaceuticals
Mapi Pharma Ltd.